We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
31
19 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
N/A
Active, not recruiting
18
58.1%
Completed
5
16.1%
Not yet recruiting
1
3.2%
Recruiting
Terminated
2
6.5%
No approval data available
- Opthea's sozinibercept (OPT-302) demonstrates potential to enhance visual outcomes in wet age-related macular degeneration patients without competing with standard anti-VEGF-A therapies. - The company's crucial COAST and ShORe trials are advancing on schedule, with results anticipated in early and mid-2025, leading to potential regulatory filing in Q1 2026. - Leading analysts, including Leerink Partners' Marc Goodman, maintain bullish outlook on Opthea's stock, highlighting the drug's commercial promise in addressing unmet needs in ophthalmology.